BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs7903146
,
KLK3
,
Coagulation
,
Arthritis
,
Embryo
,
Laryngoscope
,
Cisplatin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
bap1 protein, human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Kidney cancer UM-RC-6 cells with BAP overexpression cultured in glucose-free media
Human osteosarcoma cell line (U2OS) with BAP1 knockdown by shRNA
Explore Curated Studies Results
Literature
Most Relevant Literature
BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis.
Translated article] BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis.
Targeting BAP1 with small compound inhibitor for colon cancer treatment.
Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratif…
BAP1-deficient meningioma presenting with trabecular architecture and cytokeratin expression: a repo…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Olaparib in People With Malignant Mesothelioma
Olaparib in Patients With HRD Malignant Mesothelioma
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ